Lisa Richardson, MD
Family Medicine · Homewood, ILNPI 1992918726
Payments from drug & device makers
Across 442 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$903
- AstraZeneca$857
- Otsuka America Pharmaceutical, Inc.$692
- Boehringer Ingelheim$598
- Merck$588
- Lundbeck LLC$463
- plus $5K from 25 others
What the payments were for
- Food & beverage$8,679100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 72 | $903 |
| AstraZeneca | 40 | $857 |
| Otsuka America Pharmaceutical, Inc. | 33 | $692 |
| Boehringer Ingelheim | 26 | $598 |
| Merck | 39 | $588 |
| Lundbeck LLC | 28 | $463 |
| AbbVie(2 entities) | 31 | $459 |
| Novo Nordisk | 19 | $454 |
| Dexcom, Inc. | 20 | $387 |
| Lilly USA, LLC | 19 | $383 |
| Abbott | 5 | $379 |
| Axsome Therapeutics, Inc. | 10 | $324 |
| Novartis | 16 | $293 |
| GSK | 12 | $266 |
| Vanda Pharmaceuticals Inc. | 8 | $240 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $226 |
| Exact Sciences | 11 | $186 |
| Xeris Pharmaceuticals, Inc. | 10 | $183 |
| Sanofi-aventis U.S. LLC | 7 | $178 |
| Intuitive Surgical | 1 | $127 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Pfizer | 4 | $90 |
| Bayer | 4 | $68 |
| Sanofi Pasteur Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Ardelyx, Inc. | 1 | $35 |
| Johnson & Johnson | 2 | $29 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$319
- Ozempic$228
- Da Vinci Surgical System$127
- Auvelity$110
How this compares
$8,692 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $268,747 |
| FarxigaDapagliflozin Propanediol | 190 | $163,306 |
| JardianceEmpagliflozin | 90 | $96,113 |
| TradjentaLinagliptin | 66 | $69,415 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $60,411 |
| JanuviaSitagliptin Phosphate | 50 | $55,877 |
| MounjaroTirzepatide | 27 | $45,674 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $42,165 |
| EliquisApixaban | 33 | $36,639 |
| Repatha SureclickEvolocumab | 44 | $33,121 |
| RybelsusSemaglutide | 21 | $31,786 |
| LinzessLinaclotide | 37 | $27,997 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $25,914 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $25,664 |
| Bydureon BciseExenatide Microspheres | 15 | $25,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $454 | $300,533193 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Glyxambi | $598 | $221,328198 claims |
| AstraZenecaFarxiga | $857 | $163,306190 claims |
| MerckJanuvia, Janumet Xr | $588 | $79,05982 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $266 | $70,50686 claims |
| Lilly USA, LLCMounjaro | $383 | $45,67427 claims |
| PfizerEliquis | $90 | $36,63933 claims |
| AbbVieLinzess | $459 | $27,99737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Homewood
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.